GlassScriptPhysician profile
Brett Ozanich
NPI 1164743928
$6,400.92
in general payments reported to CMS, 2019-2025
29 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,511 · 2020: $1,279 · 2021: $714 · 2022: $763 · 2023: $625 · 2024: $584 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.58 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,083.60 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,010.65 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Janssen Biotech, INC. | $586.82 | 2019-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $418.99 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Incyte Corporation | $361.95 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $354.45 | 2019-2023 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $332.87 | 2022-2025 | Sotyktu |
| Amgen INC. | $332.64 | 2019-2023 | Otezla |
| Ucb, INC. | $257.13 | 2019-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $231.48 | 2019-2025 | |
| Galderma Laboratories, L.P. | $185.85 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $178.37 | 2019-2020 | |
| Pfizer INC. | $156.35 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $136.83 | 2025 | |
| Arcutis Biotherapeutics, INC. | $126.11 | 2024-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $114.79 | 2019 | |
| Allergan, INC. | $107.33 | 2020 | |
| Leo Pharma INC. | $98.66 | 2022-2024 | Adbry |
| Biofrontera INC. | $74.78 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Helsinn Therapeutics (U.S.), INC. | $41.89 | 2019-2023 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.17 | 2023-2025 | Spevigo, Cyltezo |
| Dermavant Sciences, INC. | $31.74 | 2023-2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $31.04 | 2021 | |
| Prugen, INC. Pharmaceuticals | $16.04 | 2019 | |
| Stimlabs LLC | $15.70 | 2025 | Corplex P |
| Bioventus LLC | $14.90 | 2023 | |
| Tactile Systems Technology INC | $14.39 | 2020 | |
| Organon LLC | $10.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Ozanich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.